Company Filing History:
Years Active: 2000-2006
Title: Innovations in Coagulation Therapy by Inventor Manuel Tsiang
Introduction
Manuel Tsiang is a notable inventor based in Foster City, California, who has made significant contributions to the field of coagulation therapy. With a portfolio of two patents, Tsiang's innovations are focused on novel polypeptides that hold tremendous potential in medical applications, particularly concerning anticoagulation and clotting therapies.
Latest Patents
Tsiang's latest patents include a groundbreaking development involving novel polypeptides (NPs) capable of activating protein C without triggering significant fibrinogen clotting activity. These polypeptides are designed to exhibit enhanced protein C activating properties in relation to fibrinogen clotting, making them particularly useful as anticoagulants. They can also be employed in screening substances that either agonize or antagonize this property. In addition, Tsiang's innovations play a critical role in diagnostic procedures used to assess the status of patients' activated protein C-mediated anticoagulant pathways. The procoagulant NPs are adept at promoting clotting during solid tumor therapies and can be used as impregnates for bandages or in diagnostic assays. These novel polypeptides can be produced in recombinant cell culture or via in vitro methods, showcasing Tsiang's commitment to advancing medical therapies.
Career Highlights
Manuel Tsiang is currently associated with Gilead Sciences, Inc., a company known for its impactful advancements in pharmaceuticals. His work entails developing therapeutic solutions that address complex medical conditions, particularly in the realm of coagulation disorders. Tsiang's dual focus on research and practical application highlights his innovative approach to solving real-world medical challenges.
Collaborations
Throughout his career, Tsiang has collaborated with esteemed colleagues, including Craig S. Gibbs and Lawrence L. Leung. Together, they have contributed to the exploration and development of innovative solutions in medical therapies, further enhancing the potential applications of Tsiang's polypeptide research.
Conclusion
In summary, Manuel Tsiang stands out as an influential inventor in the field of coagulation therapy. His latest patents promise to revolutionize how healthcare professionals approach anticoagulation and clotting challenges. With his ongoing work at Gilead Sciences, Inc. and collaborative efforts with prominent researchers, Tsiang is poised to continue making significant advancements that can improve patient outcomes in complex health scenarios.